Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012
10 January 2012 - 12:20AM
Marketwired
Stem Cell stocks -- particularly companies focused on adult stems
cells -- have performed well of late. Earlier this month Goldman
Sachs noted the potential upside of Pluristem Therapeutics --
noting that the company does not use the highly controversial
embryonic stem cells. The remark from the analyst firm helped drive
shares of similar companies that use adult stem cells. The Paragon
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on Aastrom Biosciences, Inc.
(NASDAQ: ASTM) and Cytori Therapeutics (NASDAQ: CYTX). Access to
the full company reports can be found at:
www.paragonreport.com/ASTM
www.paragonreport.com/CYTX
Cytori provides patients and physicians around the world with
medical technologies that harness the potential of adult
regenerative cells from adipose tissue. Last month Cytori filed its
Investigational Device Exemption (IDE) application to begin a
clinical trial of the Company's Celution System for chronic
myocardial ischemia (CMI).
The company is currently using fat cell-derived stem and
regenerative cells to develop treatments for heart disease and
reconstructive surgery. According to a recent article from Reuters,
to treat heart attack, a small amount of fat tissue is removed
shortly after the heart attack, stem and regenerative cells are
separated and concentrated and the cells are infused into the
coronary artery to increase blood flow.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Aastrom Biosciences' proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. This year, the company is
set to start a Phase III trial of its treatment for critical limb
ischemia (CLI), a severe form of peripheral artery disease. Aastrom
uses cells derived from a patient's own bone marrow. The company is
also conducting Phase II trials of the drug in patients with
dilated cardiomyopathy, an end-stage form of heart failure, Reuters
explains.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024